Presentation is loading. Please wait.

Presentation is loading. Please wait.

Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer  Johan F. Vansteenkiste, MD, PhD, Jean-Luc.

Published byStefan Beckers Modified over 5 years ago

Similar presentations

Presentation on theme: "Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer  Johan F. Vansteenkiste, MD, PhD, Jean-Luc."— Presentation transcript:

1 Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer  Johan F. Vansteenkiste, MD, PhD, Jean-Luc Canon, MD, Filippo De Braud, MD, Francesco Grossi, MD, Tommaso De Pas, MD, Jhanelle E. Gray, MD, Wu-Chou Su, MD, Enriqueta Felip, MD, PhD, Hiroshige Yoshioka, MD, Cesare Gridelli, MD, Grace K. Dy, MD, Sumitra Thongprasert, MD, Martin Reck, MD, PhD, Paola Aimone, MD, Gena Atalla Vidam, MS, CPM, Pantelia Roussou, PhD, Ying A. Wang, PhD, Emmanuelle Di Tomaso, PhD, Jean-Charles Soria, MD, PhD  Journal of Thoracic Oncology  Volume 10, Issue 9, Pages (September 2015) DOI: /JTO Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Waterfall plot of best percentage change in sum of diameters and best overall response, in (A) squamous and (B) nonsquamous groups. UNK indicates patients not qualifying for confirmed CR or PR and without SD after more than 5 weeks from the start of treatment. Patients assessed for best overall response but missing best percentage change from baseline are shown to the right; patients with unknown overall response and missing best percentage change from baseline are not included. One patient in the squamous group had a decrease in tumor measurement of greater than 30%, which was not confirmed at a subsequent assesment at least 4 weeks later, and was therefore classed as SD per RECIST v1.1. CR, complete response; NCRNPD, not complete response, not progressive disease; PD, progressive disease; PR, partial response; PTEN, phosphatase and tensin homolog; SD, stable disease; UNK, unknown. Journal of Thoracic Oncology  , DOI: ( /JTO ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Kaplan–Meier; plots of (A) PFS and (B) OS in squamous and nonsquamous groups. Censoring times are shown as filled or open circles. CI, confidence interval; OS, overall survival; PFS, progression-free survival. Journal of Thoracic Oncology  , DOI: ( /JTO ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer  Johan F. Vansteenkiste, MD, PhD, Jean-Luc."

Similar presentations

Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell.

Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell.
Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.
Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.
Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,
Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus  Yang Zhao, MD, ZhiJun Dai,

Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus  Yang Zhao, MD, ZhiJun Dai,
The Efficacy and Safety of BI 2536, a Novel Plk-1 Inhibitor, in Patients with Stage IIIB/IV Non-small Cell Lung Cancer Who Had Relapsed after, or Failed,

The Efficacy and Safety of BI 2536, a Novel Plk-1 Inhibitor, in Patients with Stage IIIB/IV Non-small Cell Lung Cancer Who Had Relapsed after, or Failed,
Safety and Efficacy of Dacomitinib in Korean Patients with KRAS Wild-Type Advanced Non–Small-Cell Lung Cancer Refractory to Chemotherapy and Erlotinib.

Safety and Efficacy of Dacomitinib in Korean Patients with KRAS Wild-Type Advanced Non–Small-Cell Lung Cancer Refractory to Chemotherapy and Erlotinib.
Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer  Hidenobu Ishii, MD,

Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer  Hidenobu Ishii, MD,
Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K

Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K
Gemcitabine and Irinotecan for Patients with Untreated Extensive Stage Small Cell Lung Cancer: SWOG 0119  Wallace Akerley, MD, Jason McCoy, MS, Paul J.

Gemcitabine and Irinotecan for Patients with Untreated Extensive Stage Small Cell Lung Cancer: SWOG 0119  Wallace Akerley, MD, Jason McCoy, MS, Paul J.
A New Prognostic Score Supporting Treatment Allocation for Multimodality Therapy for Malignant Pleural Mesothelioma  Isabelle Opitz, MD, Martina Friess,

A New Prognostic Score Supporting Treatment Allocation for Multimodality Therapy for Malignant Pleural Mesothelioma  Isabelle Opitz, MD, Martina Friess,
Electronic Updates for JTO Readers

Electronic Updates for JTO Readers
Can Determination of Circulating Endothelial Cells and Serum Caspase-Cleaved CK18 Predict for Response and Survival in Patients with Advanced Non–Small-Cell.

Can Determination of Circulating Endothelial Cells and Serum Caspase-Cleaved CK18 Predict for Response and Survival in Patients with Advanced Non–Small-Cell.
Asymptomatic Profound Sinus Bradycardia (Heart Rate ≤45) in Non-small Cell Lung Cancer Patients Treated with Crizotinib  Sai-Hong Ignatius Ou, MD, PhD,

Asymptomatic Profound Sinus Bradycardia (Heart Rate ≤45) in Non-small Cell Lung Cancer Patients Treated with Crizotinib  Sai-Hong Ignatius Ou, MD, PhD,
PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non-Small-Cell Lung Cancer  Denis Soulières, MD, Fred R.

PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non-Small-Cell Lung Cancer  Denis Soulières, MD, Fred R.
Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.
Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD 

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD 
Poor Prognosis Patients with Inoperable Locally Advanced NSCLC and Large Tumors Benefit from Palliative Chemoradiotherapy: A Subset Analysis from a Randomized.

Poor Prognosis Patients with Inoperable Locally Advanced NSCLC and Large Tumors Benefit from Palliative Chemoradiotherapy: A Subset Analysis from a Randomized.
Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,
A Correlative Biomarker Analysis of the Combination of Bevacizumab and Carboplatin- Based Chemotherapy for Advanced Nonsquamous Non–Small-Cell Lung Cancer:

A Correlative Biomarker Analysis of the Combination of Bevacizumab and Carboplatin- Based Chemotherapy for Advanced Nonsquamous Non–Small-Cell Lung Cancer:

Similar presentations

Ads by Google